Understanding how lung injury and repair processes work in idiopathic pulmonary fibrosis
Official title: Adhesome signaling in lung injury and repair
Funded at Birmingham VA Medical Center · NIH-10804057 · Data updated 2026-11-12
This study is looking into how a protein called TTP affects lung cells in people with idiopathic pulmonary fibrosis (IPF), a condition that causes serious lung scarring, to help find new ways to treat the disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Birmingham VA Medical Center NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| NIH project number | 1I01BX006354-01 |
| Project ID | NIH-10804057 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis, particularly those who may be veterans.
✕Less likely to help
Patients with lung diseases other than idiopathic pulmonary fibrosis may not benefit from this research.
What this research studies
This research investigates the mechanisms behind idiopathic pulmonary fibrosis (IPF), a serious lung disease characterized by excessive scarring. It focuses on a protein called Tristetraprolin (TTP), which is believed to play a crucial role in regulating the production of proteins that contribute to lung scarring. By studying how TTP functions in lung cells, the research aims to uncover why certain cells become overly active in producing scar tissue, potentially leading to new treatment strategies. The approach includes examining cell interactions and signaling pathways involved in the disease.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that slow down or reverse lung scarring in patients with idiopathic pulmonary fibrosis.
How similar studies have gone: Previous research has shown promising results in understanding the role of molecular mechanisms in lung fibrosis, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Birmingham VA Medical Center
Birmingham, United States Active
Researchers
- Principal investigator: Ding, Qiang — Birmingham VA Medical Center
- Study coordinator: Ding, Qiang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.